Patent · US Active

Anti-PD-L1 antibody and IL-7 fusions

US11401331B2 · kind B2 · utility

0Cited by

4References

6Claims

0Family size

Assignee

I-MAB BIOPHARMA US LIMITED · US

Inventors

Lei Fang · Katy, US
Feifei Cui · Shanghai, CN
Haijuan Gu · Shanghai, CN
Zhengyi Wang · Shanghai, CN
Bingshi Guo · Shanghai, CN
Jingwu Zang · Shanghai, CN

Key dates

Filing date	Jan 25, 2019
Grant date	Aug 2, 2022
Priority date	—
Expiry date	Sep 1, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/75
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are fusion molecule having a PD-L1 inhibitor fused to a human IL-7 protein or fragment thereof through a peptide linker. The disclosed fusion molecules exhibited synergistic anti-tumor effects.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.